Arturo Loaiza-Bonilla Erica Clayton Emma Furth Mark O'Hara Jennifer Morrissette
10.3332/ecancer.2014.479
Ecancermedicalscience
2014 Nov 6;8:479.
braf mek cholangiocarcinoma dabrafenib exceptional responder genomic medicine molecular tumour board next-generation sequencing personalized medicine trametinib
CC BY
https://pubmed.ncbi.nlm.nih.gov/25435907/
Case Reports
PMC4239128
25435907
Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine
2014